Three of these 15 targets—ALPL (drug: zinc sulfate), CXCL8 (drug: BMS-986253), IL6 (drug: clazakizumab, siltuximab, tocilizumab) are currently under clinical trial for COVID-19. The gene discussed is CXCL8; the disease is COVID-19.